Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide in Refractory Immune Thrombocytopenia
NCT03838354Phase 2Completed
- Sponsor
- Shandong University
- Start
- Jun 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoint: Overall response at week 12. Started Jun 2021; status: completed.
02
Drugs
tucidinostat
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03838354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838354.